World Health Organization Sounds Warning Over Severe Scarcity of Weight-Loss Medications

Fewer than one in 10 patients who could benefit from obesity jabs including Wegovy are able to get them, warns the WHO as it publishes its initial guidance on the medications.

With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable access to this class of drugs.

Based on projections, more than two billion will be obese by 2030 without intervention.

"Our latest guidance recognises that excess weight is a long-term condition that can be addressed with thorough and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are key barriers to broad availability to the injections that can help people shift considerable body mass, notes the body.

GLP-1 Therapy Supply Crisis

Even under the present most favorable outlook, the manufacturing of such drugs would only suffice for about 100 million people – under 10% of the global need, as stated by the health organization.

The advice encourages nations and manufacturers to expand access, via approaches such as patent sharing.

A patent on a key compound – the primary component of a leading brand – is scheduled to end in several nations in 2026.

The Way Weight-Loss Injections Operate

These medications mimick a biological compound to delay gastric emptying, curb appetite and boost the sense of being full so individuals consume fewer calories.

Individuals usually begin shedding pounds within a few weeks of starting on the regular doses.

Research suggests people may see weight return within a year of halting the drug, because their usual appetite resume.

To be carrying excess weight raises your likelihood for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.

Excess weight impacts people in all nations and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.